Navigation Links
Early Trial Suggests COPD Drug Might Help Some Asthmatics
Date:9/20/2010

By Steven Reinberg
HealthDay Reporter

SUNDAY, Sept. 19 (HealthDay News) -- For asthma patients whose condition is not controlled with standard inhaled steroids, the addition of Spiriva -- a medication already approved for lung disease -- appears to improve breathing, a new study finds.

However, the study authors and an outside expert stressed that these are early findings and much longer, larger clinical trials are needed.

Tiotropium bromide (Spiriva)) belongs to a class of drugs called anticholinergics, which work by enlarging the airways to allow for easier breathing. Currently, the U.S. Food and Drug Administration has only approved the medication for use by patients with chronic obstructive pulmonary disease (COPD), a chronic ailment that is a combination of bronchitis and emphysema.

Treating asthma has never been a one-size-fits-all proposition, so "having a new class of asthma medications could be potentially important," said lead researcher Dr. Stephen P. Peters, a professor of pulmonary, critical care, allergy, and immunologic medicine at Wake Forest University, in Winston-Salem, NC.

"People are different. Some people will respond to some medications, some respond to others," he said.

The report, funded by the U.S. National Heart, Lung, and Blood Institute, is published in the Sept. 19 online edition of the New England Journal of Medicine. The journal is releasing the data early to coincide with its presentation Sunday at the European Respiratory Society meeting in Barcelona.

For the study, Peters' team tried three drug regimens on 210 asthmatics. These included: Spiriva plus an inhaled steroid; a double dose of the inhaled steroid; and an inhaled steroid plus Serevent, a long-acting beta agonist that relaxes the muscles in the airway.

Patients stayed on each regiment for 14 weeks.

The researchers found that Spiriva plus an inhaled steroid was more effective than giving a double dose of steroids in improving breathing and controlling asthma for these tough-to-treat patients.

In addition, the combination of an inhaled steroid and Spiriva was not less effective than using an inhaled steroid plus Serevent, they said.

That's important, Peters said, because there have been some safety concerns raised about long-acting beta agonists. These drugs carry a note on their labels warning of the possibility of severe adverse events, including death, he noted.

The results need to be confirmed in a much larger pool of patients, Peters said, and he noted that the patients were not followed long enough to see if Spiriva was able to reduce the severity of asthma attacks and hospitalizations.

In addition, Spiriva's safety profile among asthmatics still needs to be studied, he said.

Because the drug is not yet FDA-approved for use in asthma, Peters was reluctant to recommend it for that use. "My hope is that in three to five years we will have the drug approved for asthma," he said.

Dr. Shirin Shafazand, an assistant professor of pulmonary, critical care and sleep medicine at the University of Miami Miller School of Medicine, said that "perhaps there is a role for Spiriva in these poorly controlled asthmatics."

However, at this stage there is no definitive answer whether Spiriva should or shouldn't be used in asthma, she said.

"This is a good foundation to design a trial where you would look at Spiriva plus steroids versus doubling the dose of steroids in a large number of asthmatics who are poorly controlled and then you follow them long-term," Shafazand said, but right now there is no data on long-term efficacy and safety.

More information

For more information on asthma, visit the U.S. National Library of Medicine.

SOURCES: Stephen P. Peters, M.D., Ph.D., professor, pulmonary, critical care, allergy and immunologic medicine, Wake Forest University, Winston-Salem, N.C.; Shirin Shafazand, M.D., assistant professor, pulmonary, critical care and sleep medicine, University of Miami Miller School of Medicine; Sept. 19, 2010, New England Journal of Medicine, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Prostate cancer community calls for better early detection and treatment
2. Biomarkers May Aid in Early Diagnosis of Alzheimers
3. JCI online early table of contents: Sept. 13, 2010
4. Early prostate cancer detection, screening: No benefit for men with low baseline PSA value
5. Scientists make leap forward in early detection for Alzheimers and cancer
6. Combining medication and psychosocial treatments may benefit patients with early-stage schizophrenia
7. JCI online early table of contents: Sept. 1, 2010
8. Infants gaze may be an early, but subtle, marker for autism risk
9. In Early Trial, Targeted Therapy Fights Advanced Melanoma
10. Are early testing and drug development the most pressing issues in Alzheimers care?
11. Black women with SLE develop cardiovascular disease at early age
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Early Trial Suggests COPD Drug Might Help Some Asthmatics
(Date:1/16/2017)... ... January 16, 2017 , ... ... Executive Officer of the medical device company, effective immediately. , “This is perfect ... “Kevin has a strong track record in medical device market development and revenue ...
(Date:1/15/2017)... , ... January 15, 2017 , ... Whole Health Supply, LLC is announcing the release ... are also new avenues for purchase. , The 2017 edition has wide jaws that ... for the older boomers as well as diabetics. This handle is reinforced for extra strength ...
(Date:1/15/2017)... ... 2017 , ... Wondering where to go this Valentine's Day? Well, there is ... a romantic, lobster feast in the comfort of your own home. Lobster Gram is ... will be featured until February 15th, 2017. , Romantic Dinner one is Lobster ...
(Date:1/14/2017)... ... January 13, 2017 , ... According to a December ... diet may lower the risk of type 2 diabetes, Alzheimer’s, and cardiovascular disease. ... and wellness benefits linked to a Mediterranean diet are only some of the ...
(Date:1/13/2017)... ... January 13, 2017 , ... The 18th European Congress: Perspectives in ... March 3-4, 2017. This Congress is expertly designed to meet the educational needs ... with lung cancer. , Chaired by Dr. Giorgio V. Scagliotti, Professor of Oncology at ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... Research and Markets has announced the addition of the ... Outlook, Growth Potential, Competitive Strategies and Forecasts: 2017 - 2021" ... ... the 11 major NIPT test by the year end of 2021. ... the market and contains thoughtful insights, facts, historical data, and statistically ...
(Date:1/16/2017)... NEW YORK , Jan. 16, 2017 /PRNewswire/ ... global peripherally inserted central catheters market for the ... is to offer updates and information related to ... catheters market. This comprehensive market study demonstrates the ... current environment and future status of the global ...
(Date:1/16/2017)... Inc., a leading manufacturer and marketer of imaging and respiratory ... TM Single-Use video laryngoscopes. The new Spectrum blades ... TM technology, which actively optimizes image quality. ... ... Introducing another bright idea from GlideScope(R) Video Laryngoscopes: SPECTRUM. ...
Breaking Medicine Technology: